Finoriq research workspace
Xeris Biopharma Holdings, Inc. (XERS) News
Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing. Review XERS recent headlines, source links, and company news on Finoriq.
Company Snapshot
Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. It offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase 3 clinical trial for the treatment of hypothyroidism. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.
- Company
- Xeris Biopharma Holdings, Inc. (XERS)
- Ticker
- XERS
- Market Cap
- $1.5B
- Latest Price
- $8.615
- Industry
- Biotech & Pharma
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.